[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368522-105":59,"doc-detail-368522-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pimitespib-an-hsp90-inhibitor-enhances-the-efficacy-of-parp-inhibitors-in-parp-inhibitor-insensitive-breast-cancer-cells-original-article-research-findings","Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor-Insensitive Breast Cancer Cells - Original Article - Research Findings","","Heat shock protein 90 (HSP90) regulates protein homeostasis and supports survival of cancer cells, making it a target for anticancer strategies. Pimitespib (TAS-116), an ATP-competitive inhibitor of HSP90α/β, was investigated for its ability to potentiate poly(ADP-ribose) polymerase (PARP) inhibitors. In PARP inhibitor-insensitive breast cancer cell lines, pimitespib disrupted homologous recombination by driving proteasome-mediated degradation of HR proteins including BRCA1, BRCA2, and RAD51. In xenograft mouse models, RAD51 protein levels decreased and PARP inhibitor antitumor effects increased, supporting combination therapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pimitespib-an-hsp90-inhibitor-enhances-the-efficacy-of-parp-inhibitors-in-parp-inhibitor-insensitive-breast-cancer-cells-original-article-research-findings/368522/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pimitespib-an-hsp90-inhibitor-enhances-the-efficacy-of-parp-inhibitors-in-parp-inhibitor-insensitive-breast-cancer-cells-original-article-research-findings/368522.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does HSP90 play in cancer cells, and why target it?","Question",{"text":113,"@type":114},"HSP90 acts as a molecular chaperone that supports protein folding and multiple cancer-related cellular processes. Its high expression in tumors and broad client-protein network make it a relevant target for reducing survival-promoting proteins.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does pimitespib enhance the activity of PARP inhibitors in PARP inhibitor-insensitive breast cancer cells?",{"text":118,"@type":114},"Pimitespib impaired the homologous recombination (HR) pathway by promoting proteasome-mediated degradation of HR proteins such as BRCA1, BRCA2, and RAD51. This increased DNA damage and antitumor effects induced by PARP inhibitors in vitro.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports the combination effect in vivo?",{"text":122,"@type":114},"In human breast cancer xenograft mouse models, pimitespib downregulated RAD51 proteins and augmented the antitumor effects of PARP inhibitors, aligning with the proposed mechanism of HR disruption.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368522,1790195207,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nPimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor-Insensitive Breast Cancer Cells  \nHiromi Muraoka  | Hiromi Kazuno | Akihiro Hashimoto | Hiroshi Sootome | Shuichi Ohkubo   \nDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co. , Ltd., Tsukuba, Ibaraki, Japan Correspondence: Shuichi Ohkubo ([s-ohkubo@taiho.co.jp](s-ohkubo@taiho.co.jp))  \nReceived: 30 June 2024 | Revised: 18 February 2025 | Accepted: 10 March 2025  \nKeywords: combination therapy | heat shock protein 90 | molecular targeted therapy | poly(ADP-ribose) polymerase inhibitor  \nABSTRACT  \nHeat shock protein 90 (HSP90) plays a crucial role in the maintenance of protein homeostasis in cancer cells. Inhibition of HSP90 is anticipated to exert anticancer activities by reducing levels of HSP90 client proteins. Pimitespib (TAS-116) has emerged as a potent ATP-competitive inhibitor of both HSP90α and β, demonstrating favorable therapeutic properties in preclinical models. Notably, pimitespib is the first HSP90 inhibitor approved for the treatment of advanced gastrointestinal stromal tumors in Japan. Poly(ADP-ribose) polymerase (PARP) inhibitors target cancers susceptible to the homologous recombination (HR) pathway and are used for treating various types of tumors, particularly those harboring defects in HR repair pathways within DNA damage repair (DDR) such as mutations in breast cancer genes 1 and 2 (BRCA1 and BRCA2, respectively) . However, PARP inhibitors have shown limited efficacy in HR-proficient tumors, and the development of resistance to PARP inhibitors via restoration of DDR systems poses a significant challenge. In this study, we explored the potential of pimitespib to enhance PARP inhibitor activity. In PARP inhibitor-insensitive breast cancer cell lines, pimitespib impaired HR pathway function by promoting the proteasome-mediated degradation of proteins involved in HR, such as BRCA1, BRCA2, and Rad51 homologous 1 (RAD51) . Consequently, pimitespib enhanced antitumor activity and DNA damage induced by PARP inhibitors in vitro. In human breast cancer xenograft mouse models, pimitespib downregulated RAD51 proteins and augmented the antitumor effects of PARP inhibitors. These findings highlight the potential of pimitespib as a therapeutic agent in combination with PARP inhibitors to treat PARP inhibitor-insensitive cancers.  \n1 | Introduction  \nHeat shock protein 90 (HSP90) serves as a crucial molecular chaperone that orchestrates protein folding and participatesin diverse cellular processes [1] . Its expression is elevated in numerous tumors compared to that in normal tissues, underscoring its role in regulating protein assembly and stability to maintain cancer cell survival [2, 3] . HSP90 interacts with over 200 proteins, termed client proteins, which are crucial for cell  \nfunctions such as cell cycle regulation, apoptosis, and DNA repair [4] . Although HSP90 is considered a target for cancer therapy, and several HSP90 inhibitors have been developed, many have shown undesirable dose-limiting side effects, including hepatotoxicity, neurotoxicity, and ocular toxicity [5] .  \nIn contrast, pimitespib (TAS-116) has emerged as an ATPcompetitive inhibitor targeting both HSP90α and β, showing favorable therapeutic properties in preclinical models [6] . Its  \n\n| Abbreviations: BRCA1, breast cancer gene 1; BRCA2, breast cancer gene 2; DDR, DNA damage repair; DSB, double-strand break; HR, homologous recombination; HSP, heat shock protein; PARP, poly(ADP-ribose) polymerase; RAD51, Rad51 homologous 1. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.\u003Cbr>© 2025 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanes","cbCaipIYIM97iRpB","https://ap.wps.com/l/cbCaipIYIM97iRpB","pdf",1028359,"English","# Abstract\n# Introduction\n## HSP90 as a cancer target\n## Pimitespib (TAS-116) and rationale for combination therapy\n## DNA damage repair and PARP inhibitors\n## Challenges in PARP inhibitor resistance\n# Key findings (from study overview)\n## HR pathway impairment by pimitespib\n## In vitro enhancement of PARP inhibitor effects\n## In vivo xenograft results and RAD51 downregulation","[{\"question\":\"What role does HSP90 play in cancer cells, and why target it?\",\"answer\":\"HSP90 acts as a molecular chaperone that supports protein folding and multiple cancer-related cellular processes. Its high expression in tumors and broad client-protein network make it a relevant target for reducing survival-promoting proteins.\"},{\"question\":\"How does pimitespib enhance the activity of PARP inhibitors in PARP inhibitor-insensitive breast cancer cells?\",\"answer\":\"Pimitespib impaired the homologous recombination (HR) pathway by promoting proteasome-mediated degradation of HR proteins such as BRCA1, BRCA2, and RAD51. This increased DNA damage and antitumor effects induced by PARP inhibitors in vitro.\"},{\"question\":\"What evidence supports the combination effect in vivo?\",\"answer\":\"In human breast cancer xenograft mouse models, pimitespib downregulated RAD51 proteins and augmented the antitumor effects of PARP inhibitors, aligning with the proposed mechanism of HR disruption.\"}]","Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor-Insensitive Breast Cancer Cells - Original Article - Research Findings | PDF",1790177327,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7935a277a7b5f3e5652a8bd27ee2c14c.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bbdc4d8cfca9035277b2bc2071574fd.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e35c424629d229ec6b7c5da933487005.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/749692a31b9d639739bad0e707b49ece.webp",980,1287]